Pharmaceutical News

RSS

FDA issues public health advisory for antipsychotic drugs

The Food and Drug Administration (FDA) has issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., “off-label”) use of certain drugs called “atypical antipsychotic drugs.”

12 Apr 2005

FDA wants warnings put on antipsychotic drugs

The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of “atypical antipsychotic drugs.”

11 Apr 2005

Significant progress in pSivida BioSilicon drug delivery evaluation

Global nanotechnology company pSivida Limited has announced that its evaluation of selected compounds from an undisclosed top five global pharmaceutical company has progressed successfully.

11 Apr 2005

FDA approves Ambien CR for treatment of insomnia

Sanofi-aventis announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Ambien CR (zolpidem tartrate extended release) CIV. Ambien CR is the controlled-release formulation of zolpidem, the world's leading sleep aid.

11 Apr 2005

Giuliani report calls for moratorium on prescription drug importation

As the nation tightens its borders against possible future terrorist attacks, it risks undermining security and safety by opening them to non-FDA approved prescription drugs from other countries, according to a comprehensive report released today in New York City by Giuliani Partners, headed by former New York City Mayor Rudy Giuliani.

11 Apr 2005

Increased scrutiny of new multiple sclerosis-fighting drugs after Tysabri withdrawal

The removal of Tysabri from the market soon after its introduction is expected to increase scrutiny of other similar drugs in development for multiple sclerosis (MS), says ECRI, a leading, independent health services research agency.

11 Apr 2005

Bextra withdrawn from market, strong warnings on popular painkillers

The U.S. Food and Drug Administration (FDA) has issued warnings that most popular painkillers can hurt the heart, stomach and skin, and they have told pharmaceutical giant Pfizer to withdraw Bextra a top selling painkiller.

10 Apr 2005

Test of new HIV drug

A study under way at UAB aims to determine whether the first of a new class of HIV drugs is safe and effective in preventing the virus from entering healthy cells.

10 Apr 2005

Race to market cancer vaccine

In a race to market the first vaccine against the virus that causes cervical cancer and genital warts drug manufacturers Merck & Co Inc. and GlaxoSmithKline plc are in head-to-head competition.

7 Apr 2005

pSivida moves to full development programme of pancreatic cancer product

pSivida Limited has announced that it has initiated a full development programme of its proprietary BrachySil product in a second key cancer indication. Development has commenced to evaluate the efficacy and safety of this novel brachytherapy product in pancreatic cancer, with the clinical programme scheduled to commence before the end of 2005.

7 Apr 2005

Experts available for comment on controversy over a nevirapine

The controversy over a nevirapine clinical trial conducted in the late 1990s threatens to limit the use of a drug that has saved hundreds of thousands of babies in the developing world from HIV infection, according to experts from the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA).

7 Apr 2005

Pfizer separately agrees to suspend sales of Bextra due to FDA evaluation of risks of rare but serious skin reactions

Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs such as ibuprofen and naproxen.

7 Apr 2005

Animi-3 may offer hope for rheumatoid arthritis

Animi-3, a prescription medication from PBM Pharmaceuticals, Inc., contains ingredients that may have a beneficial, protective effect in inflammatory diseases such as rheumatoid arthritis (RA).

7 Apr 2005

Pfizer withdraws Bextra from market

Despite an expert panel stating last month that the three COX-2 drugs Vioxx, Bextra and Celebrex were safe enough to be marketed, the U.S. Food and Drug Administration (FDA) has this week told drug manufacturer Pfizer to remove the drug Bextra from the market and a statement by Pfizer confirms that the European Union regulators have done the same.

7 Apr 2005

Florida sues drug company for Medicaid fraud

Charlie Crist, Florida's Attorney General is taking three pharmaceutical companies to court for $25 million, accusing them of illegally inflating prices on generic drugs used to treat depression, schizophrenia, seizures and angina.

6 Apr 2005

Branded drug companies give generics a taste of their own medicine

To defend market share, more branded drug companies today release generic versions of their branded drugs before other generic companies enter the market, according to a study by pharmaceutical intelligence firm, Cutting Edge Information.

6 Apr 2005

Pentagon too slow responding to Anthrax scare

A report by officials in Maryland, Virginia and the District of Columbia says the Pentagon was too slow in informing local officials about the recent anthrax scare in Defence Department mail facilities and gave antibiotics to workers without coordinating with public health officials. It says the Homeland Security Department (DoD) "needs to be involved earlier in such incidents".

6 Apr 2005

Britain becoming "pill for every ill" society

A report by the influential Commons Select Committee on Health, criticises the drugs industry for promoting the wider use of medication in a bid to increase its profits, and says Britain is being turned into "pill for every ill" society by the multibillion-pound drugs industry, which encourages patients to take medication even for "unhappiness".

5 Apr 2005

Canadians spend over $21 billion on drugs

Drugs continue to be the fastest-growing category of health care spending in Canada and a new report released by the Canadian Institute for Health Information (CIHI), the Drug Expenditure in Canada 1985-2004 report, shows that total spending on drugs is expected to have reached $21.8 billion in 2004, five times the amount spent on drugs in 1985.

5 Apr 2005

Genomics and proteomics to increase the efficiency of drug discovery and development

While the United Sates is still the world leader, Europe is having a good deal of success in the field of advanced genomics and proteomics research. Significant government funding together with the presence of large pharmaceutical companies has made Europe a major competitor in the efforts to deploy genomics and proteomics as vital tools in drug discovery and development.

5 Apr 2005